Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cobalt settles Imitrex litigation with Glaxo
The terms of the settlement, which remain subject to government review, provide that Cobalt may distribute a generic version of sumatriptan succinate tablets in the US with an
The terms of the settlement, which remain subject to government review, provide that Cobalt may distribute a generic version of sumatriptan succinate tablets in the US with an
VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo in the primary endpoint of the trial, sleep onset. VEC-162 was also demonstrated to be
The FDA has asked a panel of outside experts to discuss the overall risks and benefits of the antibiotic Ketek during a meeting in December, according to a
The study was designed to evaluate the safety and effectiveness of topical interferon alpha-2b in patients with cytologically confirmed low-grade squamous intraepithelial lesions and human papilloma virus infection
“In the statistical plan, a total of 364 patients would be required to obtain 90% power with a 30% allowance for drop out,” said Randall Kaye, vice president
“We are pleased that the FDA has agreed to remove the clinical hold status of the trials, and we plan to continue to work closely with UCB to
Fresenius has paid Nabi Biopharmaceuticals $65 million in cash and will pay an additional $20 million upon the successful completion of certain milestones. Fresenius has also acquired rights
Canada’s generic drug makers argue that the ban could prevent customers’ access to cheaper generic drugs and be costly for Canada’s healthcare system. “Canada’s Parliament approved legislation allowing
The companies have been awarded 180-day exclusivity for their copies of Zocor, with no rival drugs allowed to be marketed during this period. As the first company to
The trial evaluated 3% NanoEmulsion diclofenac topical cream. The analysis of the data indicates the formulation was safe with no serious adverse events. In addition, the pharmacokinetic analysis